Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis (Q28289819)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis	scientific article

Statements

scholarly article

0 references

1 reference

Europe PubMed Central

Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis (English)

0 references

relapsing-remitting multiple sclerosis

0 references

multiple sclerosis

0 references

Gillian M Keating

2

object named as

Gillian M Keating

0 references

author name string

Natalie J Carter

1

0 references

language of work or name

0 references

publication date

20 August 2010

0 references

0 references

70

0 references

12

0 references

1545-77

0 references

Etiology of aseptic meningitis and encephalitis in an adult population

1 reference

https://api.crossref.org/works/10.2165%2F11204560-000000000-00000

21 January 2018

Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.2165%2F11204560-000000000-00000

21 January 2018

Glatiramer Acetate (Copolymer-1, Copaxone) Promotes Th2 Cell Development and Increased IL-10 Production Through Modulation of Dendritic Cells

1 reference

https://api.crossref.org/works/10.2165%2F11204560-000000000-00000

21 January 2018

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

1 reference

https://api.crossref.org/works/10.2165%2F11204560-000000000-00000

21 January 2018

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.2165%2F11204560-000000000-00000

21 January 2018

Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.2165%2F11204560-000000000-00000

21 January 2018

Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.

1 reference

https://api.crossref.org/works/10.2165%2F11204560-000000000-00000

21 January 2018

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.2165%2F11204560-000000000-00000

21 January 2018

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.2165%2F11204560-000000000-00000

21 January 2018

Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained

1 reference

https://api.crossref.org/works/10.2165%2F11204560-000000000-00000

21 January 2018

Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data

1 reference

https://api.crossref.org/works/10.2165%2F11204560-000000000-00000

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.2165%2F11204560-000000000-00000

21 January 2018

Transplanted myogenic progenitor cells express neuronal markers in the CNS and ameliorate disease in experimental autoimmune encephalomyelitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New options for early treatment of multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetate.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Emerging multiple sclerosis oral therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MRI--the perfect surrogate marker for multiple sclerosis?

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glatiramer acetate: evidence for a dual mechanism of action

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinically isolated syndromes: predicting and delaying multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The importance of early diagnosis of multiple sclerosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factorin situ

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanism of action of glatiramer acetate in treatment of multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk-benefit assessment of glatiramer acetate in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MRI as an outcome in multiple sclerosis clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple sclerosis: Geoepidemiology, genetics and the environment

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early treatment of multiple sclerosis to prevent neurologic damage

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Implications of neutralising antibodies on therapeutic efficacy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral therapy for multiple sclerosis--sea change or incremental step?

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of multiple sclerosis: beyond the NICE guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of oral antihistamine on local injection site reactions with self-administered glatiramer acetate.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neurogenesis and neuroprotection in the CNS--fundamental elements in the effect of Glatiramer acetate on treatment of autoimmune neurological disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20687620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11204560-000000000-00000

0 references

Dimensions Publication ID

0 references

release_oxwfmo52vvgxpnp4nwvq4svtau

1 reference

https://api.fatcat.wiki/v0/release/oxwfmo52vvgxpnp4nwvq4svtau

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28289819&oldid=2177597223"